Lexicon Pharmaceuticals, Inc.
LXRX
$1.62
$0.010.62%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -61.27% | -50.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -61.27% | -50.87% | |||
| Cost of Revenue | -330.81% | 1,035.33% | |||
| Gross Profit | 1,164.54% | -116.85% | |||
| SG&A Expenses | 15.19% | -18.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.12% | 4.93% | |||
| Operating Income | -21.28% | -426.20% | |||
| Income Before Tax | -21.62% | -492.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -21.62% | -492.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -21.62% | -492.65% | |||
| EBIT | -21.28% | -426.20% | |||
| EBITDA | -21.82% | -407.67% | |||
| EPS Basic | -21.65% | -490.00% | |||
| Normalized Basic EPS | -21.36% | -492.86% | |||
| EPS Diluted | -21.65% | -490.00% | |||
| Normalized Diluted EPS | -21.36% | -492.86% | |||
| Average Basic Shares Outstanding | 0.01% | 0.03% | |||
| Average Diluted Shares Outstanding | 0.01% | -0.05% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||